CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...

GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...

GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance. 1w. GSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American ... driven by strong performance across all ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several ...

Read GSK PLC Sponsored ADR (NYSE:GSK) ... The institutional investor owned 305,395 shares of the pharmaceutical company’s stock after buying an additional 13,239 shares ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, ... Price Action: GSK stock is up 1.98% at $37.07 during the premarket session at the last check on Wednesday.

GSK’s Price Performance, Valuation & Estimate Movement. GSK stock has risen 20.1% year to date compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and ...